Bone marrow fibrosis is a critical component of primary myelofibrosis (PMF). However, the origin of the myofibroblasts that drive fibrosis is unknown. Using genetic fate mapping we found that bone marrow leptin receptor (Lepr )-expressing mesenchymal stromal lineage cells expanded extensively and were the fibrogenic cells in PMF. These stromal cells downregulated the expression of key haematopoietic-stem-cell-supporting factors and upregulated genes associated with fibrosis and osteogenesis, indicating fibrogenic conversion. Administration of imatinib or conditional deletion of platelet-derived growth factor receptor a (Pdgfra) from Lepr + stromal cells suppressed their expansion and ameliorated bone marrow fibrosis. Conversely, activation of the PDGFRA pathway in bone marrow Lepr + cells led to expansion of these cells and extramedullary haematopoiesis, features of PMF. Our data identify Lepr + stromal lineage cells as the origin of myofibroblasts in PMF and suggest that targeting PDGFRA signalling could be an effective way to treat bone marrow fibrosis.
Haematopoietic stem cells (HSCs) are maintained by their microenvironmental niches. Recently, we identified bone marrow Lepr + mesenchymal stromal cells as a critical component of the niche that elaborates multiple factors, including stem cell factor (SCF) and CXCL12 (refs 1,2) . These stromal cells include skeletal stem cells, which are the main source of bone in the adult bone marrow 3 . Although our understanding of the mesenchymal stromal cells under steady state has advanced quickly, how these cells are altered by and contribute to haematological diseases has not been well characterized 4 .
Primary myelofibrosis (PMF) is a subtype of myeloproliferative neoplasms (MPNs) with clinical characteristics, including anaemia, bone marrow fibrosis and extramedullary haematopoiesis 5 . Most PMF patients are elderly. PMF originates clonally from abnormal haematopoietic stem/progenitor cells. Allogeneic HSC transplantation is the only possible cure. However, this approach is too toxic for elderly people, precluding its application to most PMF patients. The haematopoietic-intrinsic molecular mechanisms that lead to PMF have been studied extensively 6 . Several driver mutations have been identified, including JAK2V617F and MPLW515L mutations that lead to constitutive activation of JAK2 kinase and the upstream receptor MPL, respectively 6 . Calreticulin mutations that activate the MPL receptor [7] [8] [9] have recently been discovered in most JAK2/MPL mutation-negative patients 10, 11 . Thus, activation of the MPL-JAK-STAT pathway in haematopoietic cells is a general feature of MPNs, regardless of the specific molecular mechanisms. Consistent with this, a comprehensive genomic analysis has identified gene signature of JAK-STAT activation in all MPN patients, independent of mutations 12 . At present JAK inhibitors are being actively explored as a means to treat PMF. Although these inhibitors control symptoms, they do not resolve the disease, particularly the bone marrow fibrosis 6 . Thus a deeper understanding of the fibrotic component of PMF pathogenesis is required to devise more effective therapies.
The cellular mechanisms underlying bone marrow fibrosis are still being elucidated. An earlier study of X-chromosome-linked markers in a female PMF patient revealed that haematopoietic cell overproliferation was clonal whereas the bone marrow fibrosis was not 13 . Mouse models with MPN-associated mutations have demonstrated that MPNs originate from abnormal haematopoietic clones 14 , but how overproliferating haematopoietic cells lead to bone marrow fibrosis and extramedullary haematopoiesis is not clear. Megakaryocyte deregulation and hyperplasia is a defining cellular feature of PMF 6, 15 . Overexpression of the major megakaryopoietic cytokine, thrombopoietin (TPO), leads to megakaryocyte hyperplasia and PMF in mice 16, 17 . Gata1 low mice with a block in megakaryocyte maturation 18 developed myelofibrosis, suggesting a disease model where dysregulated megakaryocytes secrete excessive cytokines, including transforming growth factor-beta 1 (Tgfβ1) and plateletderived growth factor (PDGF), that drive bone marrow fibrosis 19 .
Indeed, targeting deregulated megakaryocytes by inhibiting the AURKA pathway eliminated bone marrow fibrosis 20 . However, the bone marrow stromal cells that respond to the cytokines elaborated by hyperplastic megakaryocytes and that directly deposit reticulin and collagen fibres have not been identified.
PDGFs are potent cytokines that promote mesenchymal cell proliferation and are implicated in many fibrotic diseases, including pulmonary and liver fibrosis 21 . Activation of platelet-derived growth factor receptor a (PDGFRA) signalling is sufficient to drive fibrosis in diverse organs 22, 23 . PMF patients have significantly higher concentrations of PDGFs in circulation, probably due to increased release 24 . However, whether PDGFR pathways play a role in bone marrow fibrosis has not been directly addressed.
It has been speculated that cells of the fibroblastic lineage are the origin of myofibroblasts in PMF 5, 25 . A number of markers have been used to identify mouse bone marrow fibroblastic stromal cells, also referred to as colony-forming unit-fibroblasts (CFU-F), including nestin-GFP (green fluorescent protein), CD51, PDGFRA, PDGFRB and NG2 (refs [26] [27] [28] [29] [30] . Using some of these markers, several studies characterized the mesenchymal stromal cells in MPN mouse models. In a chronic myeloid leukaemia model, an expansion of Lin − CD45 − CD31 − CD51 + Sca1 − osteoblastic lineage cells and increased collagen deposition were reported 31 . However, it was not clear whether these cells were the origin of bone marrow fibrosis. In a Jak2 V617F MPN model, lineage tracing was carried out using Nestin-creER to assess the contribution of nestin + stromal cells 32 . No obvious contribution of these cells to bone marrow fibrosis was noted 32 . As a result, the stromal cells that directly contribute to bone marrow fibrosis are unknown. Given the central role of PDGFR signalling in myofibroblasts and fibrosis, we searched for bone marrow stromal cells that express PDGFRs. Previously, we reported that Lepr + stromal cells are uniformly positive for PDGFRA and PDGFRB 1, 3 . Conversely, virtually all PDGFR + stromal cells in the bone marrow are Lepr + (ref. 3) . This raises the question of whether the Lepr + PDGFR + stromal cells are the origin of myofibroblasts in PMF.
We set out to identify the stromal cells that generate reticulin and collagen fibre in myelofibrosis using lineage tracing. We found that Lepr + mesenchymal stromal cells were the source of myofibroblasts and underwent expansion in PMF. These cells downregulated key HSC maintenance factors and upregulated fibrogenic and osteogenic genes. Conditional deletion of Pdgfra from Lepr + mesenchymal stromal cells or administration of imatinib suppressed their expansion and largely abolished bone marrow fibrosis. Conversely, activation of the PDGFRA pathway in Lepr + mesenchymal stromal cells led to their expansion and extramedullary haematopoiesis. Our results identify the activation of the PDGFRA pathway in Lepr + cells as an important contributor to myelofibrosis, and provide a proof of principle that inhibiting the PDGFRA pathway in mesenchymal stromal cells is an attractive strategy to treat bone marrow fibrosis.
RESULTS

Development of PMF in Tpo-overexpressing mice
We adapted a retroviral mouse PMF model by transplanting Tpo-overexpressing (TOE) retrovirally infected bone marrow cells into irradiated mice. Consistent with prior reports 16, 17 , these mice developed high levels of serum TPO (Fig. 1a ), thrombocythemia ( Fig. 1b ) and a trend towards leukocytosis ( Fig. 1c ) within three months of the transplantation. The bone marrow from the TOE mice was pale, particularly in mice with advanced PMF (Fig. 1d ). Enlarged spleens with extramedullary haematopoiesis were evident, accompanied by a threefold increase in spleen weight ( Fig. 1e ,f). Bone marrow myeloid cells significantly expanded in TOE mice (58 ± 13% cells were myeloid cells in TOE versus 40 ± 8% in controls) ( Fig. 1g ). These mice displayed megakaryocyte hyperplasia in the bone marrow ( Fig. 1h ) and profound fibrosis in the spleen and bone marrow ( Fig. 1i,j) . Large numbers of collagen fibres and osteosclerosis associated with fibrosis made dissociation of bone marrow cells from TOE mice into single-cell suspension difficult. These observations indicate that the TOE model developed features of PMF as previously reported 16, 17 .
HSCs undergo proliferation and mobilization in TOE mice
We examined HSC and progenitor compartments in TOE mice 2-4 months after the bone marrow transplantation. There was a fivefold increase of the frequency of Lin − Sca1 + cKit + CD150 + CD48 − HSCs in the bone marrow of TOE mice when compared with mice transplanted with control-virus-infected bone marrow cells ( Fig. 2a,b) . Similarly, Lin − Sca1 + cKit + CD150 − CD48 − multipotent progenitors and Lin − Sca1 + cKit + haematopoietic progenitor cells (HPCs) were also significantly increased ( Fig. 2a and Supplementary Fig. 1a ). Bone marrow cellularity was significantly reduced in TOE mice ( Fig. 2c ). An overall quantification revealed an increase of HSC number in TOE bone marrow ( Fig. 2d ). There were variations among the TOE mice in term of haematopoietic phenotypes, presumably due to the variable amount of TPO (thus variable fibrosis induction strength) in individual mice. When the mice were grouped into intermediate and advanced stages on the basis of their haematopoietic parameters (for example colour of bone marrow and ease of bone marrow dissociation), we observed an initial significant increase of bone marrow HSC number in intermediate followed by a reduction of HSCs in advanced PMF mice ( Fig. 2e ), consistent with clinical data on different stages of PMF patients 33 . Multipotent progenitors and HPCs showed similar alterations ( Supplementary Fig. 1a ). This is associated with a gradual depletion of bone marrow cellularity ( Fig. 2f ). HSCs from TOE mice incorporated more bromodeoxyuridine (BrdU) in five-day pulse experiments ( Fig. 2g and Supplementary Fig. 1b ), suggesting they proliferated more.
There was a 1.6-fold increase of mechanically dissociable cells in the spleens from TOE mice ( Fig. 2h ). This was probably an underestimate, because dissociation of TOE spleens was difficult due to extensive fibrosis. HSC frequency and number increased significantly in the TOE spleens ( Fig. 2i ,j). HSCs shifted from the bone marrow to the spleen in advanced PMF mice ( Fig. 2k and Supplementary Fig. 1c-f ). Overall, total HSC number first increased in intermediate PMF followed by a reduction in advanced PMF ( Supplementary Fig. 1g ). These data suggest a pathogenic process of PMF: HSCs initially overproliferate and start mobilizing to the spleen; as the disease progresses, the bone marrow becomes fibrotic and hypocellular, and many HSCs shift to the spleen in advanced stages of PMF. (i,j) HSC frequency and number from spleens of TOE mice were significantly increased (n = 22 mice for control and n = 23 mice for TOE in i; n = 13 mice for control and n = 11 mice for TOE in j). (k) Quantification of spleen and bone marrow HSC number showed a significant mobilization to the spleen in the advanced stage of PMF (n = 12 mice for control, n = 6 mice for intermediate PMF and n = 7 mice for advanced PMF). Int., intermediate stage.
Adv., advanced stage. All data represent mean ± s.e.m. Two-tailed Student's t-tests were used to assess statistical significance: * P < 0.05, * * P < 0.01, * * * P < 0.001.
Lepr + mesenchymal stromal cells undergo fibrotic expansion
The above data suggest that bone marrow fibrosis contributes to bone marrow haematopoietic failure. However, the identity of cells that deposit collagen fibres and render bone marrow fibrotic is elusive. Bone marrow Lepr + mesenchymal stromal cells, which uniformly express PDGFRA and PDGFRB 1,3 , arise perinatally and are major contributors to bone formed in adults but not during development 3 . They give rise to nearly all CFU-Fs in adult bone marrow and can differentiate into bone, cartilage and adipocytes in vitro and in vivo 3 . These observations prompted us to test whether Lepr + stromal cells are responsible for bone marrow fibrosis in vivo.
The frequency of enzymatically dissociated CD45/Ter119 − PDGFRA + stromal cells significantly increased in TOE mice ( Fig. 3a and Supplementary Fig. 2a ). The Lepr-cre knock-in allele recombines specifically in PDGFRA + bone marrow mesenchymal stromal cells 1, 3 . We fate-mapped Lepr + lineage cells using Lepr-cre; tdTomato mice in which PMF was induced by transplanting TOE-retrovirus-infected bone marrow cells ( Fig. 3b ). Consistent with the increased stromal cell frequency ( Fig. 3a and Supplementary Fig. 2a ), tdTomato + cells expanded dramatically in TOE mice when compared with mice transplanted with bone marrow cells infected with control virus (Fig. 3c-f and Supplementary Fig. 2b ). These tdTomato + stromal lineage cells elaborated extensive cellular processes resembling myofibroblasts (Fig. 3e,f and Supplementary Fig. 2c,d ), suggesting that these cells assumed a fibrotic cell fate.
To directly assess whether the Lepr + stromal cells are the myofibroblastic cells, we used Collagen1a1-GFP (Col-GFP) reporter mice 34 , in which Collagen1a1-expressing myofibroblastic cells are labelled in multiple organs 23, 35, 36 . We generated Lepr-cre; tdTomato; Col-gfp mice to examine whether tdTomato + cells are Col-GFP + in the PMF bone marrow. In Lepr-cre; tdTomato; Col-gfp mice without PMF induction, sparse tdTomato + cells and Col-GFP + cells overlapped ( Fig. 3g -i), suggesting that Lepr + stromal cells expressed collagen and had some fibrogenic capacity even at steady state. We then induced PMF by transplanting TOE-virus-infected bone marrow cells into these mice. At 3-4 months after the transplantation, mice were analysed. Consistent with our earlier observation, tdTomato + stromal lineage cells underwent a significant expansion in TOE bone marrow ( Fig. 3j-o ). Virtually all of the tdTomato + cells were Col-GFP + (Fig. 3j-o and Supplementary Fig. 2e ). Conversely, virtually all Col-GFP + cells were tdTomato + (Fig. 3j-o and Supplementary  Fig. 2f ). These data demonstrate that Lepr + lineage cells are the major if not exclusive source of myofibroblasts responsible for fibrosis in the PMF bone marrow.
Mesenchymal stromal cells downregulate key niche factors for HSCs
Lepr + mesenchymal stromal cells play a critical role in bone marrow HSC maintenance by generating key niche factors, CXCL12 and SCF 1,2,37 . Bone marrow Lepr + cells, Cxcl12 high cells and Scf high cells are essentially the same mesenchymal population [1] [2] [3] . Fibrogenic conversion of these cells may alter their capacity to support HSCs. We examined the niche function of these cells in PMF by evaluating the expression of key niche-derived HSC maintenance factors. We directly assessed CXCL12 expression in the bone marrow from Cxcl12 DsRed/+ knock-in mice 2 with PMF induction. Cxcl12 DsRed/+ mice reconstituted with empty-vector-virus-infected bone marrow cells were used as controls. The expression level of Cxcl12-DsRed was reduced in TOE mice when compared with controls, although the frequency of these cells did not seem to change as revealed by confocal microscopy (Fig. 4a-d and Supplementary Fig. 3a-d ) and by flow cytometry (Fig. 4e ). Quantification of the intensity of Cxcl12-DsRed and quantitative real-time PCR analysis showed that there was a significant reduction of DsRed expression level and Cxcl12 transcripts by mesenchymal stromal cells (Fig. 4f-h and Supplementary Fig. 3e ). Many of the Cxcl12-DsRed + stromal cells displayed elongated fibroblast-like cell morphology ( Supplementary  Fig. 3c,d) , consistent with the notion that these cells adopted a fibrogenic cell fate. Since CXCL12 is a major HSC retention signal 2, 38 , its downregulation provides a potential mechanistic explanation for HSC mobilization out of the bone marrow in PMF.
Taking advantage of an Scf gfp/+ knock-in reporter 1 , we assessed the expression of Scf -GFP + in the PMF bone marrow. There was a downregulation of Scf -GFP expression level in the PMF bone marrow revealed by confocal microscopy (Fig. 4i-l) . By flow cytometry, the frequency of CD45/Ter119 − Scf -GFP + stromal cells did not differ significantly between TOE and control bone marrow ( Fig. 4m and Supplementary Fig. 3f ). The Scf -GFP expression level at singlecell resolution was significantly reduced in PMF bone marrow as assessed by flow cytometry (Fig. 4n,o) . Quantitative real-time PCR analysis also showed a significant reduction of Scf transcripts ( Fig. 4p and Supplementary Fig. 3e ). Overall, the above data suggest that adaptation of a fibrotic cell fate by mesenchymal stromal cells leads to lower expression of key HSC niche factors and thus compromised bone marrow niche.
Mesenchymal stromal cells undergo fibrotic conversion/differentiation in PMF
We carried out a genome-wide gene expression profiling to molecularly characterize the mesenchymal stromal cells in PMF. We sorted CD45/Ter119 − Cxcl12-DsRed + mesenchymal stromal cells, as Cxcl12 expression is a direct marker for functional HSC niche cells. Although Cxcl12-DsRed is expressed by other bone marrow cells at low levels 2 and its expression level was downregulated about fourfold ( Fig. 4f ,g), our sorting strategy purified most mesenchymal stromal cells expressing high levels of DsRed ( Supplementary  Fig. 4a ). As expected, these cells also expressed high levels of mesenchymal markers such as Pdgfra(CD140a), Pdgfrb(CD140b) and Lepr ( Supplementary Fig. 4b ). CD45/Ter119 − Cxcl12-DsRed + cells expressed very little, if any, Nestin or Ng2 ( Supplementary Fig. 4b ). Statistical analysis identified 480 upregulated genes (P < 0.05, more than 1.5-fold) and 146 downregulated genes (P < 0.05, more than 1.5-fold) from TOE mice when compared with controls ( Fig. 5a ). Gene ontology analysis using the Database for Annotation, Visualization and Integrated Discovery (DAVID) identified several significantly enriched processes, including extracellular matrix, cell adhesion and proteinaceous extracellular matrix ( Fig. 5b ), suggesting a fibrotic conversion/differentiation of these cells.
To systematically test whether these cells underwent fibrotic conversion, we carried out gene set enrichment analysis (GSEA). A mouse fibrosis gene set was obtained from Qiagen (www.qiagen.com), which includes 85 key genes involved in dysregulated tissue (c-f) Lepr-cre; tdTomato mice were transplanted with TOE-virus-infected bone marrow cells or control-virus-infected bone marrow cells. Two to three months after the transplantation, the fate of Lepr-cre-expressing lineage cells was followed by assessing the tdTomato + cells. remodelling during the repair and healing of wounds ( Supplementary  Fig. 4c ). We found that Cxcl12 + mesenchymal stromal cells from PMF bone marrow expressed many genes associated with fibrosis (normalized enrichment score (NES) = 3.32, false discovery rate (FDR) q = 0 and p = 0) ( Fig. 5c ). Using a published fibrosis gene signature from in vivo fibrotic liver stellate cells 39 , we carried out an independent GSEA analysis. Again, PMF mesenchymal stromal cells significantly expressed many genes associated with liver stellate cell fibrosis (NES = 1.65, FDR q = 0 and p = 0), confirming their fibrotic conversion (Fig. 5d ). Since Lepr + stromal cells are the main source of bone formed in the adult bone marrow 3 and osteosclerosis is a feature of myelofibrosis 40 , we tested whether the PMF mesenchymal stromal cells globally upregulated osteoblastic genes. A mouse osteogenesis gene set was obtained from Qiagen (www.qiagen.com), which includes 82 genes related to osteogenic differentiation ( Supplementary Fig. 4d) . A GSEA analysis revealed that PMF mesenchymal stromal cells significantly expressed many osteogenic genes (NES = 1.7, FDR q = 0 and p = 0) ( Fig. 5e ). mesenchymal stromal cells underwent global gene expression change to a fibrotic/osteogenic fate in the PMF bone marrow.
Genes that were significantly more highly expressed in PMF mesenchymal stromal cells included genes encoding extracellular matrix: Acta2 (a smooth muscle actin), Fn (fibronectin), several collagens (Col12a1, Col1a1, Col1a2 and Col3a1) and integrins (Itgbl1, Itga2 and Itgb5) (Supplementary Table 1 ). Extracellular matrix remodelling enzymes were also upregulated, including Mmp9 (matrix metallopeptidase 9), Timp1 (tissue inhibitor of metalloproteinase 1), Mmp2 (matrix metallopeptidase 2), Timp3 (tissue inhibitor of metalloproteinase 3) and Mmp14 (matrix metallopeptidase 14) (Supplementary Table 1 ). Several highly upregulated genes associated with osteogenesis included Postn (periostin, osteoblast-specific factor), Spp1 (secreted phosphoprotein 1, osteopontin) and Alpl (alkaline phosphatase, liver/bone/kidney) (Supplementary Table 1 ). We also observed a significant reduction of Lepr ( Supplementary  Table 1 ), although the expression level was still high ( Supplementary  Fig. 4b) . A recent study reported that LepR from bone marrow stromal cells promotes adipogenesis and inhibits osteogenesis 41 . The downregulation of Lepr is consistent with the elevated osteogenesis of these cells in PMF. In line with our analysis on niche factor expression ( Fig. 4) , we also observed downregulation of Cxcl12 and Scf ( Supplementary Fig. 4b ). Altogether, these data demonstrate that bone marrow mesenchymal stromal cells undergo fibrotic conversion/differentiation and are thus probably the origin of myofibroblasts responsible for fibrosis in the PMF bone marrow.
PDGFRA in mesenchymal stromal cells is required for bone marrow fibrosis
The identification of Lepr + mesenchymal stromal lineage cells as bone marrow myofibroblasts in PMF provided us with an opportunity to investigate the molecular pathways involved in their fibrotic conversion. Activation of PDGFRA has been implicated in fibrosis of multiple organs 22, 23 . As Lepr + mesenchymal stromal cells are the major cell type expressing PDGFRA in the bone marrow 1 , we wondered whether PDGFRA in mesenchymal stromal cells is required for their fibrotic conversion. We conditionally deleted Pdgfra from bone marrow mesenchymal stromal cells by generating Lepr-cre; Pdgfra fl/fl or Lepr-cre; Pdgfra fl/− mice. PDGFRA was efficiently deleted from bone marrow mesenchymal stromal cells ( Supplementary Fig. 5a ). Bone marrow cells from these mice had normal reconstitution activity when transplanted into lethally irradiated recipient mice ( Supplementary Fig. 5b ). We induced
PMF by transplanting TOE-virus-infected bone marrow cells into
Lepr-cre; Pdgfra fl/fl and control mice. At 2-3 months after the bone marrow transplantation, HSC frequencies from Lepr-cre; Pdgfra fl/fl and control mice were similarly increased in the spleen (Fig. 6a ). This was accompanied by enlarged spleens with probable ongoing extramedullary haematopoiesis (Fig. 6b,c and Supplementary Fig. 5c ). Reticulin staining on spleen sections from Lepr-cre; Pdgfra fl/fl mice demonstrated excessive deposition of reticulin fibres to the same extent as those from control TOE mice ( Supplementary Fig. 5d ). These data reveal that Lepr-cre; Pdgfra fl/fl TOE mice developed many features of PMF in the spleen.
Myeloid proliferation and HSC expansion occurred similarly in Lepr-cre; Pdgfra fl/fl TOE and control TOE mice (Fig. 6d ). There was a significant rescue of the bone marrow cellularity in Lepr-cre; Pdgfra fl/fl mice (Fig. 6e ), suggesting an improvement of the bone marrow niche function. Megakaryocyte hyperplasia was similar in Lepr-cre; Pdgfra fl/fl and control TOE mice ( Supplementary Fig. 5e ). We then examined bone marrow fibrosis by performing reticulin staining. Consistent with our earlier observation ( Fig. 1j ), excessive reticulin fibre deposition was observed in the bone marrow from control TOE mice ( Fig. 6f , upper panels and Supplementary Fig. 5f ). In contrast, we did not observe reticulin staining in the bone marrow from Lepr-cre; Pdgfra fl/fl TOE mice (Fig. 6f , lower panels and Supplementary Fig. 5f ). Consistent with the ameliorated fibrosis, flushing the bone marrow cells out of the bone from Lepr-cre; Pdgfra fl/fl TOE mice was dramatically easier when compared with fibrotic control TOE bone marrow, probably due to the absence of excessive fibrosis and osteosclerosis. The increased frequency of mesenchymal stromal lineage cells was suppressed to almost vector control level in Lepr-cre; Pdgfra fl/fl TOE mice ( Fig. 6g and Supplementary Fig. 5g ). Several fibrotic genes, such as Col1a1, Col3a1 and Acta2, were significantly downregulated in Lepr-cre; Pdgfra fl/fl TOE mice (Fig. 6i) . Thus, PDGFRA signalling in Lepr + mesenchymal stromal cells is required for bone marrow fibrosis in PMF. These data functionally show that bone marrow Lepr + mesenchymal stromal cells are the cell type responsible for fibrosis in PMF.
Imatinib effectively blocks the activity of several tyrosine kinases, including PDGFRA 42 . We assessed whether imatinib treatment would alleviate bone marrow fibrosis. PMF was induced in TOE mice and then imatinib was administrated through chow. Imatinib effectively rescued bone marrow hypocellularity and blocked mesenchymal stromal cell expansion, fibrotic conversion and bone marrow fibrosis (Fig. 6e,g-i) . Imatinib also effectively suppressed spleen extramedullary haematopoiesis and fibrosis, suggesting that other cell types and/or pathways may mediate PMF spleen pathogenesis (Fig. 6a-c and Supplementary Fig. 5c,h) . Our results suggest that targeting PDGFRA pathway in mesenchymal stromal cells may be beneficial in treating bone marrow fibrosis.
Activation of PDGFRA in Lepr + bone marrow mesenchymal stromal cells leads to their expansion and extramedullary haematopoiesis
To directly test whether activation of the PDGFRA pathway in mesenchymal stromal cells has an impact on PMF pathogenesis, we conditionally activated PDGFRA by generating Lepr-cre; Pdgfra D842V/+ ; tdTomato mice (Fig. 7a) . The Pdgfra D842V allele allows for cell-type-specific activation of the PDGFRA pathway under the control of its endogenous promoter 22, 23 . By flow cytometry, bone marrow stromal cell frequency was largely unchanged in Lepr-cre; Pdgfra D842V/+ mice ( Supplementary Fig. 6a ). However, by confocal microscopy, we observed foci with a significant increase of tdTomato + stromal cells in the trabecular bone region of Lepr-cre; Pdgfra D842V/+ ; tdTomato mice ( Fig. 7b-d) . We also observed excessive osteogenesis in the diaphysis region of these mice (Fig. 7e,f) . However, no excessive bone marrow fibrosis was observed ( Supplementary Fig. 6b ).
Lepr-cre; Pdgfra D842V/+ mice had normal bone marrow cellularity and HSC frequency ( Fig. 7g and Supplementary Fig. 6c ). However, these mice had increased HSC and haematopoietic progenitor frequencies in the spleens and livers (Fig. 7h-j and Supplementary  Fig. 6d ). These results suggest that activation of the PDGFRA pathway in Lepr + cells is sufficient to cause some features of PMF: mesenchymal stromal cell expansion, osteogenesis and HSC mobilization.
DISCUSSION
Although PMF has been recognized as a haematological disease originating from abnormal HSCs, its clinical features suggest a more complex pathogenesis. The bone marrow fibrosis associated with PMF has been hypothesized as a stromal reaction to the overproliferative haematopoietic clones, but the precise identity of the reactive myofibroblasts had not previously been identified. Our fate-mapping data demonstrate that Lepr + mesenchymal stromal cells are the cells of origin of myofibroblasts responsible for collagen fibre generation and deposition in PMF. The identification of these cells warrants further detailed investigation aimed at developing targeted therapies to treat bone marrow fibrosis.
In this study we observed expansion of bone marrow Lepr + mesenchymal stromal lineage cells in PMF (Fig. 3a,c-f and Supplementary Fig. 2a-d) . A report using Nestin as a marker suggests that bone marrow stromal cell number is reduced in Jak2 V617F mice 32 . The authors carried out Nestin-creER fate mapping and did not observe any contribution from this lineage to myofibroblasts. Several previous studies have shown that Nestin-cre or Nestin-creER recombines only in rare bone marrow stromal cells 1, 3, 43 . These cells are not CFU-Fs and make little, if any, contribution to skeletal tissues 3, 43 . Thus, Nestin-creER probably does not target mesenchymal stromal cells. It should be noted that, although low expression of a Nestin-GFP transgene is a marker for CFU-F, the expression of endogenous Nestin, or other Nestin transgenic lines (including Nestin-cre or Nestin-CreER), does not mark the same mesenchymal stromal cells 1, 3, 43 . Thus, our data are consistent with the notion that Lepr + stromal cells and not Nestin + , Nestin-cre + or Nestin-creER + cells are the source of bone marrow myofibroblasts in PMF.
NG2 + cells have been reported to contain bone marrow CFU-Fs 29 . However, a fate-mapping experiment demonstrated that Ng2-creER + cells did not contribute to PDGFRA + stromal cells 29 , suggesting that these cells are unlikely to be the source of bone marrow fibrosis. Gli1 + and Gremlin-1 + bone marrow stromal cells also contain CFU-Fs 43, 44 . Their contributions to bone marrow fibrosis are unknown. The contributions to bone marrow fibrosis by distinct yet overlapping mesenchymal stromal cells bearing different markers require further investigations. Figure 6 Deletion of Pdgfra from mesenchymal stromal cells or administrating imatinib ameliorates bone marrow fibrosis. (a) Lepr-cre; Pdgfra fl/fl TOE mice had an increase of spleen HSC frequency similar to that of control TOE mice, whereas imatinib suppresses HSC mobilization. Vector, vector in control; Con, TOE in control; Mut, TOE in Lepr-cre; Pdgfra fl/fl ; imatinib, TOE treated with imatinib (n = 22 mice for vector, n = 10 mice for Con, n = 8 mice for Mut, n = 7 mice for imatinib). (b,c) Lepr-cre; Pdgfra fl/fl TOE mice but not imatinibtreated TOE mice displayed increased spleen weight (b) (n = 18 mice for vector, n = 8 mice for Con, n = 7 mice for Mut, n = 7 mice for imatinib) and cellularity (c) (n = 15 mice for vector, n = 7 mice for Con, n = 7 mice for Mut, n = 7 mice for imatinib) when compared with control TOE mice. (d) Bone marrow (BM) from Lepr-cre; Pdgfra fl/fl TOE or imatinib-treated TOE mice had no significant change in HSC frequency, compared with control TOE mice (n = 21 mice for vector, n = 10 mice for Con, n = 8 mice for Mut, n = 7 mice for imatinib). (e) Lepr-cre; Pdgfra fl/fl TOE and imatinib-treated TOE mice had a significant increase of bone marrow cellularity when compared with control TOE mice (n = 21 mice for vector, n = 10 mice for Con, n = 8 mice for Mut, n = 7 mice for imatinib). (f) Deletion of Pdgfra from mesenchymal stromal cells led to blockage of reticulin deposition in the bone marrow from Lepr-cre; Pdgfra fl/fl TOE mice. (g) Deletion of Pdgfra from Lepr + stromal cells or administration of imatinib led to suppression of the overproliferation of bone marrow CD45/Ter119 − PDGFRB + mesenchymal stromal cells in TOE mice (n = 17 mice for vector, n = 8 mice for Con, n = 6 mice for Mut, n = 7 mice for imatinib). (h) Administration of imatinib led to blockage of reticulin fibre deposition in the bone marrow of TOE mice. (i) Deletion of Pdgfra from Lepr + stromal cells or administration of imatinib suppresses fibrotic genes in bone marrow mesenchymal stromal cells (n = 4 mice for vector, n = 4 mice for Con, n = 4 mice for Mut, n = 4 mice for imatinib). Data represent mean ± s.d. Two-tailed Student's t-tests were used to assess statistical significance: * P < 0.05, * * P < 0.01, NS, not significant. Lepr-cre; Pdgfra D842V/+ mice had normal bone marrow (BM) HSC frequency (g) (n = 4 mice for control, n = 5 mice for D842V) and spleen cellularity (h) (n = 5 mice for control, n = 6 mice for D842V). (i,j) Lepr-cre; Pdgfra D842V/+ mice displayed increased HSC (i) (n = 5 mice for control, n = 6 mice for D842V) and HPC (Lin − Sca1 + cKit + ) (j) (n = 5 mice for control, n = 6 mice for D842V) frequencies in the spleen. Data represent mean ± s.d. Two-tailed Student's t-tests were used to assess statistical significance: * P < 0.05, * * * P < 0.001. Images are representative of at least three biological replicates.
Our Lepr-cre; Pdgfra fl/fl TOE mice still developed severe spleen fibrosis ( Supplementary Fig. 5d ). It could be that Lepr-cre does not target all of the spleen fibrogenic cells and/or that PDGFRA is not required for spleen fibrosis. Over-activation of PDGFRA is sufficient to drive fibrosis in diverse organs 22, 23 . We thus favour the first possibility. Identification of the spleen fibrogenic cells will directly distinguish these possibilities. Recently, spleen Tcf21 + perivascular stromal cells have been identified as an important component of the spleen niche 45 . It will be interesting to determine the relative contributions of the Tcf21 + and Lepr + cells to spleen fibrosis. Imatinib exerted more potent effects against bone marrow fibrosis and HSC mobilization than genetic deletion of Pdgfra from Lepr + cells ( Fig. 6 and Supplementary Fig. 5 ). Given that imatinib targets several tyrosine kinases, including BCR-ABL, PDGFR and c-KIT, it is likely that the additional molecular and cellular targets account for the stronger effects of the drug.
Lepr-cre; Pdgfra D842V/+ mice showed regional stromal cell expansion and HSC mobilization ( Fig. 7) . However, the phenotypes were not as pronounced as the TOE model. This could reflect the partial activation of the PDGFRA pathway in the D842V model 22 . However, other pathways could be cooperating in TOE to induce more prominent PMF pathology. Further elucidation of the PDGFRA and other pathways in PMF will deepen our understanding of the pathogenesis.
The modification of the bone marrow niche by abnormal haematopoietic cells is a critical contributor to many haematological diseases 4 . Consistent with early observations 15 , our data suggest that hyperplastic megakaryocytes are the source of PDGF and other cytokines promoting bone marrow mesenchymal stromal cell fibrosis and HSC niche dysfunction. Current therapies for PMF focus on the haematopoietic compartment by targeting the mutant haematopoietic clones, but the overall benefits are limited. Imatinib mesylate has been preliminarily explored in PMF 46, 47 , but its clinical benefits were limited due to side effects. Our results call for additional detailed study. We propose that combined therapy against both the mutant haematopoietic clone (for example with JAK inhibitors) and the dysfunctional, fibrotic bone marrow niche (for example, with imatinib or other PDGFRA inhibitors) with a careful treatment regimen may lead to better outcome.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of this paper. Supplementary Figure 3 Bone marrow mesenchymal stromal cells down-regulate CXCL12 and SCF, and display a fibrotic cell morphology.
(Related to Fig. 4) Tgfb1  Tgfb2  Tgfb3  Tgfbr1  Tgfbr2  Tgif1  Thbs1  Thbs2  Timp1  Timp2  Timp3  Timp4 Tnf Vegfa Tgfb1  Tgfb2  Tgfb3  Tgfbr1  Tgfbr2  Tgfbr3  Tnf  Tnfsf11  Twist1 Figure 6 Lepr-cre; Pdgfra D842V/+ mice have bone marrow stromal fibrotic conversion and HSC mobilization (Related to Fig. 7 ) a. Flow cytometry analysis revealed normal bone marrow stromal cell frequency from Lepr-cre; Pdgfra D842V/+ mice (n=3 mice for control, n=4 mice for D842V KI). b. Representative reticulin staining on bone marrow sections from Lepr-cre; Pdgfra D842V/+ and control mice. c. Normal bone marrow cellularity (n=4 mice for control, n=5 mice for D842V KI) and HPC frequency of Lepr-cre; Pdgfra D842V/+ mice (n=5 mice for control, n=6 mice for D842V KI). d. HSC frequency in livers from Lepr-cre; Pdgfra D842V/+ mice (n=5 mice for control, n=6 mice for D842V KI). Data represent mean±s.d.. Two-tailed student's t-tests were used to assess statistical significance. Images are representative of at least 3 biological replicates. 
